TQB2450 + AL2846 + pemetrexed + cisplatin

A four-drug combination regimen of **TQB2450** (an anti–PD-L1 monoclonal antibody immune checkpoint inhibitor), **AL2846** (a multi-targeted small molecule antiangiogenic tyrosine kinase inhibitor), **pemetrexed** (an antimetabolite antifolate chemotherapy agent), and **cisplatin** (a platinum-based alkylating-like chemotherapy agent). This combination is under clinical investigation primarily for patients with advanced non-small cell lung cancer (NSCLC), including those with prior immunotherapy failure[1][3][5][6]. The rationale is to combine immune checkpoint inhibition, angiogenesis inhibition, and DNA synthesis inhibition for enhanced antitumor efficacy.